METHODS OF TREATMENT COMPRISING STABLE REDUCED GLUTATHIONE
The present disclosure is drawn to a method of treating a subject having a condition responsive to treatment with reduced glutathione (rGSH), comprising: administering a therapeutically effective amount of a substantially α-D-glucopyranoside-free stabilized rGSH composition to the subject.
1 . A method of treating a subject having a condition responsive to treatment with reduced glutathione (rGSH), comprising:
administering a therapeutically effective amount of a substantially α-D-glucopyranoside-free stabilized rGSH composition to the subject.
2 . The method of claim 1 , wherein the condition is a skin condition.
3 . The method of claim 2 , wherein the skin condition is selected from the group consisting of: psoriasis, eczema, acne, hives, warts, cold sores, candidiasis, athlete's foot, wounds, mouth wounds, mouth pain, burns, sunburns, dry skin, wrinkles, blisters, actinic keratosis, rosacea, carbuncles, cellulitis, contact dermatitis, and keratosis pilaris.
4 . The method of claim 3 , wherein the skin condition is one of a burn, a wound, or eczema, and the rGSH is present in the composition in an amount of from about 50 mg to about 1500 mg.
5 - 6 . (canceled)
7 . The method of claim 4 , further comprising administering the composition to the subject according to a dosage regimen.
8 - 10 . (canceled)
11 . The method of claim 7 , wherein symptoms of the condition are reduced by at least about 10% since commencement of the treatment.
12 . The method of claim 2 , wherein the composition is in a topical dosage form.
13 . The method of claim 12 , wherein the composition further comprises a stabilizing carrier.
14 . The method of claim 13 , wherein the stabilizing carrier comprises deoxygenated water.
15 . The method of claim 13 , wherein the stabilizing carrier consists essentially of deoxygenated water.
16 . The method of claim 14 , wherein the stabilizing carrier further comprises a solution, a suspension, an emulsion, a gel, a hydrogel, a thermo-responsive gel, a cream, a paste, or an ointment.
17 - 18 . (canceled)
19 . The method of claim 2 , further comprising co-administering an active agent to the subject.
20 . The method of claim 19 , wherein the co-administration is concomitant administration.
21 . The method of claim 20 , wherein the active agent is in the same or a different composition as the rGSH.
22 . The method of claim 19 , wherein the active agent is a member selected from the group consisting of: an antioxidant, an antibiotic, an antiviral, an antitoxin agent, hydroxytyrosol (HXT), superoxide dismutase (SOD), catalase, an anti-infective agent, an anti-tumor agent, an anti-inflammatory agent, an analgesic, an anti-rheumatic agent, a growth factor, a cytokine, an amino acid, a protein, a vaccine, a hormone, a vitamin, oleuropein, the like, and combinations thereof.
23 . The method of claim 20 , wherein the condition is a burn and the active agent is an antibiotic.
24 . The method of claim 20 , wherein the condition is a wound and the active agent is an antibiotic.
25 . The method of claim 20 , wherein the condition is eczema and the active agent is an antioxidant.
26 - 131 . (canceled)
132 . The method of claim 1 , wherein more than about 80% of the rGSH remains in a reduced form upon administration to the subject.
133 . The method of claim 1 , wherein more than about 50% of the rGSH remains in a reduced form upon reaching a situs of action in the subject.
134 - 135 . (canceled)